MedTrace Logo

Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy

NCT00595699 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2011-07-18

No results posted yet for this study

Summary

This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy. The purpose of the study is to measure the severity and change in depressive and anxiety symptoms after 10 weeks of study treatment with escitalopram or placebo as measured by certain rating scales and questionnaires. In addition, the study will measure the frequency of seizures using a patient diary during the study. Finally, the study will assess the change in the quality of life using rating scales.

Conditions

Interventions

DRUG

escitalopram

10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study

DRUG

placebo

Placebo

Sponsors & Collaborators

  • Forest Laboratories

    collaborator INDUSTRY

  • Conrad, Erich J., M.D.

    lead OTHER

Principal Investigators

  • Erich J Conrad, M.D · LSUHSC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00595699 on ClinicalTrials.gov